NCT02143882View on ClinicalTrials.gov

A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).

PHASE4CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions

Live Attenuated Influenza Vaccine

Interventions

DRUG

Fluenz

Live attenuated influenza vaccine

Trial Locations (2)

Unknown

Gloucestershire, Gloucestershire

Hertfordshire, Hertfordshire

All Listed Sponsors

collaborator

Institute of Child Health

OTHER

lead

Public Health England

OTHER_GOV

NCT02143882 - A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™). | Biotech Hunter | Biotech Hunter